1. Home
  2. INSM vs KB Comparison

INSM vs KB Comparison

Compare INSM & KB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • KB
  • Stock Information
  • Founded
  • INSM 1988
  • KB 2008
  • Country
  • INSM United States
  • KB South Korea
  • Employees
  • INSM N/A
  • KB N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • KB Commercial Banks
  • Sector
  • INSM Health Care
  • KB Finance
  • Exchange
  • INSM Nasdaq
  • KB Nasdaq
  • Market Cap
  • INSM 29.0B
  • KB 28.6B
  • IPO Year
  • INSM 2000
  • KB N/A
  • Fundamental
  • Price
  • INSM $182.69
  • KB $83.88
  • Analyst Decision
  • INSM Strong Buy
  • KB
  • Analyst Count
  • INSM 19
  • KB 0
  • Target Price
  • INSM $171.12
  • KB N/A
  • AVG Volume (30 Days)
  • INSM 2.1M
  • KB 104.1K
  • Earning Date
  • INSM 10-30-2025
  • KB 10-23-2025
  • Dividend Yield
  • INSM N/A
  • KB 2.34%
  • EPS Growth
  • INSM N/A
  • KB 32.22
  • EPS
  • INSM N/A
  • KB 10.75
  • Revenue
  • INSM $447,022,000.00
  • KB $10,605,244,059.00
  • Revenue This Year
  • INSM $40.09
  • KB $13.83
  • Revenue Next Year
  • INSM $129.64
  • KB $1.93
  • P/E Ratio
  • INSM N/A
  • KB $7.46
  • Revenue Growth
  • INSM 30.34
  • KB 6.05
  • 52 Week Low
  • INSM $60.40
  • KB $46.38
  • 52 Week High
  • INSM $197.08
  • KB $92.39
  • Technical
  • Relative Strength Index (RSI)
  • INSM 67.29
  • KB 58.63
  • Support Level
  • INSM $178.76
  • KB $80.06
  • Resistance Level
  • INSM $197.08
  • KB $82.48
  • Average True Range (ATR)
  • INSM 7.01
  • KB 1.39
  • MACD
  • INSM 1.60
  • KB 0.26
  • Stochastic Oscillator
  • INSM 65.96
  • KB 83.75

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About KB KB Financial Group Inc

KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.

Share on Social Networks: